Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status approved; investigational
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 62350-0077; 68682-272; 72189-084; 0168-0432; 22365-121; 51672-4174; 99207-271; 66039-829; 71052-160; 64552-4008; 45802-368; 51552-1538; 62147-0087; 51672-4145; 63629-8818; 68462-536; 51927-0168; 72643-006; 0093-3133; 99207-260; 99207-270; 99207-276; 58175-0397; 62147-0072
UNII P1QW714R7M
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lip blister07.05.01.007; 23.03.01.0160.000658%-
General physical health deterioration08.01.03.0180.001317%-
Balance disorder08.01.03.081; 17.02.02.0070.000439%-
Application site hyperaesthesia08.02.01.023; 12.07.01.023; 17.02.06.011---
Application site paraesthesia08.02.01.026; 12.07.01.026; 17.02.06.012---
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.012---
Lupus-like syndrome10.04.03.003; 15.06.02.004; 23.03.02.0040.001536%-
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Conjunctival hyperaemia06.04.01.0040.000878%-
Skin induration23.03.03.0200.001493%
Eye pruritus06.04.05.0060.001097%-
Application site discharge08.02.01.039; 12.07.01.039; 23.03.03.049---
Respiratory tract congestion22.02.07.003---
Lymphatic disorder01.09.01.003---
Musculoskeletal stiffness15.03.05.0270.001185%-
Protein urine present13.13.02.006---
Musculoskeletal discomfort15.03.04.001---
Application site swelling08.02.01.027; 12.07.01.0270.001185%-
Skin burning sensation17.02.06.009; 23.03.03.021---
Scrotal erythema21.12.02.008; 23.03.06.013---
Eczema weeping23.03.04.022---
Haemorrhage24.07.01.0020.001317%-
Pre-existing disease08.01.03.059---
Cutaneous lupus erythematosus10.04.03.007; 15.06.02.007; 23.03.02.0080.001097%-
Rectal tenesmus07.03.03.001; 15.05.03.011---
Cognitive disorder17.03.03.003; 19.21.02.0010.001097%
Skin oedema23.06.04.001---
Application site discolouration08.02.01.030; 12.07.01.030; 23.03.03.0230.001185%-
Application site scar08.02.01.033; 12.07.01.033; 23.03.11.0100.000878%-
Congenital eye disorder03.01.01.002; 06.08.03.011---
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene